HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor that carries a 5-y survival rate of 5%. Attempts at eliciting a clinically relevant anti-GBM immune response in brain tumor patients have met with limited success, which is due to brain immune privilege, tumor immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtin, James F, Liu, Naiyou, Candolfi, Marianela, Xiong, Weidong, Assi, Hikmat, Yagiz, Kader, Edwards, Matthew R, Michelsen, Kathrin S, Kroeger, Kurt M, Liu, Chunyan, Muhammad, A. K. M. Ghulam, Clark, Mary C, Arditi, Moshe, Comin-Anduix, Begonya, Ribas, Antoni, Lowenstein, Pedro R, Castro, Maria G
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621261/
https://www.ncbi.nlm.nih.gov/pubmed/19143470
http://dx.doi.org/10.1371/journal.pmed.1000010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621261/
https://www.ncbi.nlm.nih.gov/pubmed/19143470
http://dx.doi.org/10.1371/journal.pmed.1000010

Ejemplares similares